Protocol Ledger

NCT06555640 · Phase II · COMPLETED

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Interventional Phase II clinical trial protocol NCT06555640 sponsored by Zhejiang Doer Biologics Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-01 Enrollment: 79 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06555640
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)79 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06555640
Protocol FieldVerified Registry Value
NCT IdentifierNCT06555640
Consolidated Lead SponsorZhejiang Doer Biologics Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment79 participants (ACTUAL)
Registered Start Date2024-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06555640
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
The Second Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI